Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288053714> ?p ?o ?g. }
- W4288053714 endingPage "1554" @default.
- W4288053714 startingPage "1554" @default.
- W4288053714 abstract "The use of in vitro human skin permeation tests is of value when addressing the quality and equivalence of topical drug products in Europe and the US. Human skin is the membrane of choice for these studies. The use of human skin as a membrane is hindered by limited access, high variability of results, and limited applicability for drugs with low skin permeability. Reconstructed human epidermis (RhE) models are validated as skin surrogates for safety tests and have been explored for percutaneous absorption testing. Clotrimazole poorly permeates human skin and is widely available for topical treatments. In this study, clotrimazole creams were used to test the ability of RhE to be used as biological membrane for bioequivalence testing, based on the Draft Guideline on Quality and Equivalence of Topical Products (CHMP/QWP/708282/2018) using a discriminative and modified in vitro permeation test (IVPT). To fulfill the validation of a discriminatory method, Canesten® 10 mg/g cream was compared with a test product with the same drug strength, along with two “negative controls” dosed at a 50% and 200% drug strength. Products were compared in finite dose conditions, regarding maximal flux (Jmax) and the total amount of drug permeated (Atotal). The results showed the discriminatory power of the method among the three drug strengths with no interference of the placebo formulation. The study design and validation complied with the requirements established in the guideline for a valid IVPT. This new test system allowed for the equivalence comparison between test and comparator product. Higher permeability of the RhE compared to human skin could be observed. This arose as a strength of the model for this modified IVPT bioequivalence testing, since comparing permeation profiles among products is envisaged instead of drawing absolute conclusions on skin permeation extent. These results may support the acceptance of RhE as biological membranes for modified IVPT in bioequivalence testing of topical products." @default.
- W4288053714 created "2022-07-28" @default.
- W4288053714 creator A5001459260 @default.
- W4288053714 creator A5032629815 @default.
- W4288053714 creator A5042565383 @default.
- W4288053714 creator A5063121873 @default.
- W4288053714 creator A5068121859 @default.
- W4288053714 creator A5070906178 @default.
- W4288053714 creator A5079192812 @default.
- W4288053714 creator A5082668892 @default.
- W4288053714 date "2022-07-26" @default.
- W4288053714 modified "2023-10-11" @default.
- W4288053714 title "Reconstructed Human Epidermis: An Alternative Approach for In Vitro Bioequivalence Testing of Topical Products" @default.
- W4288053714 cites W1210654754 @default.
- W4288053714 cites W1251710288 @default.
- W4288053714 cites W1526602508 @default.
- W4288053714 cites W1546887953 @default.
- W4288053714 cites W171100415 @default.
- W4288053714 cites W1963545236 @default.
- W4288053714 cites W1965310771 @default.
- W4288053714 cites W1982030251 @default.
- W4288053714 cites W1993566237 @default.
- W4288053714 cites W2000574141 @default.
- W4288053714 cites W2002218627 @default.
- W4288053714 cites W2014632350 @default.
- W4288053714 cites W2017415014 @default.
- W4288053714 cites W2035363854 @default.
- W4288053714 cites W2041600315 @default.
- W4288053714 cites W2046393507 @default.
- W4288053714 cites W2051499702 @default.
- W4288053714 cites W2054557776 @default.
- W4288053714 cites W2056310240 @default.
- W4288053714 cites W2058441531 @default.
- W4288053714 cites W2061958341 @default.
- W4288053714 cites W2074332569 @default.
- W4288053714 cites W2076931244 @default.
- W4288053714 cites W2080654157 @default.
- W4288053714 cites W2085370181 @default.
- W4288053714 cites W2087674698 @default.
- W4288053714 cites W2094758674 @default.
- W4288053714 cites W2097695518 @default.
- W4288053714 cites W2099452046 @default.
- W4288053714 cites W2130033860 @default.
- W4288053714 cites W2138053223 @default.
- W4288053714 cites W2150933325 @default.
- W4288053714 cites W2162845988 @default.
- W4288053714 cites W2335692993 @default.
- W4288053714 cites W2417125096 @default.
- W4288053714 cites W2538241771 @default.
- W4288053714 cites W2769829505 @default.
- W4288053714 cites W2885443305 @default.
- W4288053714 cites W2970296348 @default.
- W4288053714 cites W2979236558 @default.
- W4288053714 cites W2981717444 @default.
- W4288053714 cites W2990186619 @default.
- W4288053714 cites W2999420236 @default.
- W4288053714 cites W3008377463 @default.
- W4288053714 cites W3090812988 @default.
- W4288053714 cites W3094221160 @default.
- W4288053714 cites W3152662437 @default.
- W4288053714 cites W3155703610 @default.
- W4288053714 cites W3196002498 @default.
- W4288053714 cites W4236929073 @default.
- W4288053714 cites W89775403 @default.
- W4288053714 doi "https://doi.org/10.3390/pharmaceutics14081554" @default.
- W4288053714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35893811" @default.
- W4288053714 hasPublicationYear "2022" @default.
- W4288053714 type Work @default.
- W4288053714 citedByCount "4" @default.
- W4288053714 countsByYear W42880537142023 @default.
- W4288053714 crossrefType "journal-article" @default.
- W4288053714 hasAuthorship W4288053714A5001459260 @default.
- W4288053714 hasAuthorship W4288053714A5032629815 @default.
- W4288053714 hasAuthorship W4288053714A5042565383 @default.
- W4288053714 hasAuthorship W4288053714A5063121873 @default.
- W4288053714 hasAuthorship W4288053714A5068121859 @default.
- W4288053714 hasAuthorship W4288053714A5070906178 @default.
- W4288053714 hasAuthorship W4288053714A5079192812 @default.
- W4288053714 hasAuthorship W4288053714A5082668892 @default.
- W4288053714 hasBestOaLocation W42880537141 @default.
- W4288053714 hasConcept C105795698 @default.
- W4288053714 hasConcept C112705442 @default.
- W4288053714 hasConcept C136229726 @default.
- W4288053714 hasConcept C185592680 @default.
- W4288053714 hasConcept C205679159 @default.
- W4288053714 hasConcept C2777459323 @default.
- W4288053714 hasConcept C2777789335 @default.
- W4288053714 hasConcept C33923547 @default.
- W4288053714 hasConcept C41625074 @default.
- W4288053714 hasConcept C42404028 @default.
- W4288053714 hasConcept C48002344 @default.
- W4288053714 hasConcept C50670333 @default.
- W4288053714 hasConcept C54355233 @default.
- W4288053714 hasConcept C55493867 @default.
- W4288053714 hasConcept C71924100 @default.
- W4288053714 hasConcept C86803240 @default.
- W4288053714 hasConcept C98274493 @default.
- W4288053714 hasConceptScore W4288053714C105795698 @default.